Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1? ; volume:6 ; number:1 ; day:3 ; month:12 ; year:2018 ; pages:1-4 ; date:12.2018
Journal for ImmunoTherapy of Cancer ; 6, Heft 1 (3.12.2018), 1-4, 12.2018
- Urheber
-
Zhang, Yaxiong
Zhou, Huaqiang
Zhang, Li
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40425-018-0427-6
- URN
-
urn:nbn:de:101:1-2019011922223562527214
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:02 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Zhang, Yaxiong
- Zhou, Huaqiang
- Zhang, Li
- SpringerLink (Online service)
Ähnliche Objekte (12)
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1
Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1
Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study
Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers
The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1
Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy